<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993743</url>
  </required_header>
  <id_info>
    <org_study_id>Chen Zhinan-1</org_study_id>
    <nct_id>NCT03993743</nct_id>
  </id_info>
  <brief_title>A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>An Open-label, Dose Escalation Clinical Study to Access the Safety and Clinical Activity of CD147-targeted CART by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, single-arm, open label and dose escalation clinical study of&#xD;
      anti-CD147 CART cells by hepatic artery infusions in patients with advanced hepatocellular&#xD;
      carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients autologous T cells are activated and then engineered to express chimeric antigen&#xD;
      receptors (CARs) specific for CD147(CD147-CART). CAR-T cells are expanded in culture and&#xD;
      returned to the patient by hepatic artery infusion at specific cell doses. Four CD147-CART&#xD;
      doses patient are planned at 1-week intervals. Tumor biopsies will be obtained at the time of&#xD;
      the initial diagnostic angiogram and during the first infusion session. Serum cytokine level&#xD;
      and CAR-T cell number will be measured in whole treatment session.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2019</start_date>
  <completion_date type="Anticipated">May 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and type of adverse events induced by CD147-CART hepatic artery infusions</measure>
    <time_frame>12 weeks</time_frame>
    <description>To assess the safety of CD147-CART (anti-CD147 CAR-T cell) hepatic artery infusions (HAI) for very advanced hepatocellular carcinoma which measured by number and type of adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DLT and MTD of CD147-CART cell hepatic artery infusions</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the dose limited toxicity (DLT) and maximum tolerated dose (MTD) of CD147-CART hepatic artery infusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of CD147-CART cell hepatic artery infusions</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate treatment response of CD147-CART hepatic artery infusions for very advanced hepatocellular carcinoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD147-CART detection in extrahepatic sites</measure>
    <time_frame>2 years</time_frame>
    <description>Quantification of CD147-CART cells in blood samples.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>CD147-CART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusions of CD147-CART cells over the course of each week for 3 times into the hepatic artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD147-CART</intervention_name>
    <description>Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery.</description>
    <arm_group_label>CD147-CART</arm_group_label>
    <other_name>anti-CD147 chimeric antigen receptor T cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 year and ≤ 65 years, both male and female.&#xD;
&#xD;
          2. Advanced hepatocellular carcinoma(HCC) patient, which is untreatable by surgery or&#xD;
             local therapy, or has postoperative progressions, failed at least one and two line of&#xD;
             standard systemic chemotherapy, and unwilling or intolerance to targeting therapy or&#xD;
             immune-therapy of cancer.&#xD;
&#xD;
          3. The portal vein is not total occlusion, or collateral circulation has formed between&#xD;
             hepatic artery and blocked portal vein.&#xD;
&#xD;
          4. Patient with measurable HCC focus defined by mRECIST.&#xD;
&#xD;
          5. Patient with histologically confirmed diagnosis of CD147+ hepatocellular carcinoma.&#xD;
&#xD;
          6. Adequate venous access for apheresis, and no other contraindications for apheresis.&#xD;
&#xD;
          7. Child-Pugh score ≤7.&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group(ECOG) performance status of 0-2.&#xD;
&#xD;
          9. Patient with a life expectancy of greater than three months.&#xD;
&#xD;
         10. Patients must able to understand and be willing to sign an informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with fibrolamellar carcinoma of liver，mixed hepatocellular carcinoma or&#xD;
             cholangiocarcinoma.&#xD;
&#xD;
          2. Patients with severe hypohepatia including jaundice, hepatic encephalopathy,&#xD;
             refractory ascites or hepatorenal syndrome.&#xD;
&#xD;
          3. Patients with severe comorbidity, including any of the following.&#xD;
&#xD;
               1. Unstable angina pectoris and/or congestive heart failure need hospitalization;&#xD;
&#xD;
               2. Myocardial infarction or cerebrovascular accident (CVA) in the last 6 months;&#xD;
&#xD;
               3. chronic obstructive pulmonary disease progressions or need hospitalization;&#xD;
&#xD;
               4. severe cardiovascular, nervous system, hematological, gastrointestinal, endocrine&#xD;
                  diseases or metabolic disorders;&#xD;
&#xD;
               5. autoimmune disease or immunodeficiency disease;&#xD;
&#xD;
               6. acute bacterial infections or fungal infections needs intravenous injection of&#xD;
                  antibiotics during CAR-T cell therapy;&#xD;
&#xD;
               7. tuberculosis not cured;&#xD;
&#xD;
               8. other malignancies;&#xD;
&#xD;
          4. Patients who have received gene therapy, cell therapy or immune therapy.&#xD;
&#xD;
          5. Patients who have received organ transplantation.&#xD;
&#xD;
          6. Patients who have received treatment of targeted drugs, glucocorticoid or&#xD;
             immunosuppressive drugs within 2 weeks before enrolling in clinical trial.&#xD;
&#xD;
          7. Patients who have received chemotherapy except for lymphocyte clearance within 2 weeks&#xD;
             before enrolling in clinical trial.&#xD;
&#xD;
          8. Patients who have received radiotherapy.&#xD;
&#xD;
          9. Patients who did not recover to CTCAE(v5.0) grade 1 from adverse events （except&#xD;
             hair）of previous anti-tumor therapy before enrolling in trial.&#xD;
&#xD;
         10. Syphilis test (TRUST) positive, Anti-HIV positive, Anti-HCV positive with HCV-RNA&#xD;
             level higher than the lower limit of detection(LOD), or HBcAb positive with HBV-DNA&#xD;
             level higher than the LOD.&#xD;
&#xD;
         11. Patients with following abnormalities:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &lt; 1.5E9/L, platelet(PLT) &lt; 50E9/L, or&#xD;
                  hemoglobin(HGB)&lt; 80 g/dL;&#xD;
&#xD;
               2. Prothrombin time (PT), activated partial thromboplastin time (APTT) or&#xD;
                  international normalized ratio (INR) &gt; 1.5×ULN (upper normal value);&#xD;
&#xD;
               3. Total bilirubin(TBIL) &gt; 2×ULN; ALT, AST or ALP&gt;5×ULN;&#xD;
&#xD;
               4. Serum creatinine (Cr)≥1.5×ULN or glomerular filtration rate (GFR) &lt; 60&#xD;
                  mL/min·1.73m^2;&#xD;
&#xD;
               5. left ventricular ejection fraction (LVEF) &lt; 50%;&#xD;
&#xD;
         12. Patients with a history of allergic reactions attributed to any agents or compounds&#xD;
             involved in this study.&#xD;
&#xD;
         13. Patients with a history of mental disorders.&#xD;
&#xD;
         14. Patients with a history of drug abuse.&#xD;
&#xD;
         15. Pregnant and lactating women.&#xD;
&#xD;
         16. Patients of childbearing age who unwilling or unable to take birth control from during&#xD;
             this study and 3 months post this study.&#xD;
&#xD;
         17. Patients who receive any other investigational agents within the 3 months before&#xD;
             enrolling in this clinical trial.&#xD;
&#xD;
         18. Investigator considers not suitable for this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhi-Nan Chen, PhD</last_name>
    <phone>86-029-84774547</phone>
    <email>znchen@fmmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaishan Tao, Dr</last_name>
    <phone>86-029-84775259</phone>
    <email>taokaishan0686@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of hepato-biliary &amp; Pancreato Splenic Surgery Organ Transplant Center, Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaishan Tao, Dr</last_name>
      <email>taokaishan0686@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 19, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>August 24, 2019</last_update_submitted>
  <last_update_submitted_qc>August 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Air Force Military Medical University, China</investigator_affiliation>
    <investigator_full_name>Chen Zhinan</investigator_full_name>
    <investigator_title>Director of National Translational Science Center for Molecular Medicine</investigator_title>
  </responsible_party>
  <keyword>liver cancer</keyword>
  <keyword>CD147</keyword>
  <keyword>CAR-T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

